51.8 F
New York
Monday, October 3, 2022

Date:

Share:

Parvus Therapeutics Announces CEO, Senior Executive, and Board of Directors Appointments

Related Articles

South San Francisco, CA, July 06, 2021 –(PR.com)– Parvus Therapeutics Announces CEO, Senior Executive, and Board of Directors Appointments

– Peter M. Strumph, Chief Executive Officer
– Brendan Classon PhD, Executive Vice President, Research and Development
– Louis Demers, Vice President of Technical Operations
– Matthew J. Hogan, member of the Board of Directors

Parvus Therapeutics, a biopharmaceutical company focused on the development of medicines using the proprietary platform-based, disease-specific immunoregulator, Navacims™, to treat autoimmune diseases without impairing normal immunity, today announced the appointment of Peter Strumph as Chief Executive Officer and a member of the Board of Directors, Matthew J. Hogan as a member of the Board of Directors, Brendan Classon as Executive Vice President, Research and Development, and Louis Demers as Vice President of Technical Operations.

“Parvus’ Navacim technology has the…

Read more…

Popular Articles